In the Press

Moderna will turn to a biotech startup, National Resilience, to manufacture additional doses of its Covid-19 vaccine.

Borne by mosquitoes, these diseases have a very high mortality rate in infected, unvaccinated horses – between 30 and 40 percent for West Nile and 90 percent for EEE.

Vaccines against SARS-CoV-2 are highly effective in preventing COVID-19 illness.

“We’re doing amazingly” at sequencing virus samples, but challenges remain

The SARS-CoV-2 Alpha (B117) variant spread faster and more efficiently than previous strains among children 9 years and younger in Israel in late 2020 and early 2021, even amid the concurrent immunization of adults against COVID-19, according to an observational study yesterday in JAMA Network Open.

A new technology that can study which therapies will work on patients with solid cancerous tumors has been developed by scientists at UCL.

Antimicrobial resistance in Neisseria gonorrhoeae has reached an alarming level, severely impacting the effective treatment of gonorrhea.

As Australia ponders the challenge of reopening with COVID-19 still present in our communities, the discourse from government has focused on vaccination targets.

The FDA approved the combination of daratumumab and hyaluronidase-fihj (Darzalex FASPRO) and pomalidomide and dexamethasone (Pd) for treatment of patients with multiple myeloma after a first or subsequent relapse, manufacturer Janssen announced on Monday.

Researchers at the Francis Crick Institute working with collaborators at the University of Leicester have identified how gene expression changes during different stages of tuberculosis (TB), including early after infection before any symptoms are clinically detectable.